According to Zacks, “Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company’s product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China. “
Other equities analysts have also issued reports about the stock. BidaskClub lowered shares of Zai Lab from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 12th. ValuEngine raised shares of Zai Lab from a “hold” rating to a “buy” rating in a report on Thursday, February 7th. Finally, Credit Suisse Group started coverage on shares of Zai Lab in a report on Tuesday, January 29th. They set an “outperform” rating and a $34.70 target price for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. Zai Lab presently has a consensus rating of “Buy” and an average target price of $34.57.
NASDAQ:ZLAB opened at $29.38 on Friday. The company has a market cap of $1.71 billion, a PE ratio of -11.13 and a beta of 1.22. Zai Lab has a 1-year low of $14.29 and a 1-year high of $33.86.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. increased its holdings in shares of Zai Lab by 67.4% during the third quarter. BlackRock Inc. now owns 106,059 shares of the company’s stock worth $2,066,000 after buying an additional 42,691 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Zai Lab during the third quarter worth $333,000. Jane Street Group LLC acquired a new position in shares of Zai Lab during the third quarter worth $707,000. Man Group plc acquired a new position in shares of Zai Lab during the third quarter worth $585,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Zai Lab during the third quarter worth $974,000. 36.48% of the stock is owned by hedge funds and other institutional investors.
About Zai Lab
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.
Featured Story: Backdoor Roth IRA
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.